BiopharmaTrend.com

A fresh viewpoint on drug discovery, pharma, and biotech

Subscribe | Become an author | Author LogIn

Topic: ‘In Silico’


How Big Pharma Adopts AI To Boost Drug Discovery

   by Andrii Buvailo    14086

(Last updated 08.10.2018)

The type of artificial intelligence (AI) which scares some of the greatest minds, like Elon Musk and Stephen Hawking, is called “general artificial intelligence” -- the one which can “think” pretty much like humans do, and which can quickly evolve into a dangerous “superintelligence”. There is a notion that it might be invented in the nearest decades, but today we are definitely not there yet. The AI which is making headlines these days is a “narrow artificial intelligence”, a limited type of machine “intelligence” able to solve only a specific task or a group of tasks. It can’t go anywhere beyond specifics of the problem for which it is designed, so apparently, it will not hurt anyone in the nearest time. But already now it can provide meaningful practical results on those narrow tasks, like natural language processing, image recognition, controlling self-driving cars, and helping develop new drugs more efficiently. With the ability to find hidden and unintuitive patterns in vast amounts of data in ways that no human can do, AI represents a considerable promise to transform many industries, including pharma and biotech.  

Navigating In REAL Chemical Space To Find Novel Medicines (Now 3.8 Billion Molecules)

   by Andrii Buvailo    2036
Navigating In REAL Chemical Space To Find Novel Medicines (Now 3.8 Billion Molecules)

[Latest update: 27.07.2018]

February 6 2018 will be marked in history as the day when an automobile embarked on a million year trip into far space. On that day, Falcon Heavy, the 230ft megarocket, successfully launched from Cape Canaveral, Florida, bringing on board Elon Musk’s personal Tesla Roadster with a crash test dummy called 'Starman' strapped into the driver's seat.

"The imagery of it is something that's going to get people excited around the world." says Elon Musk, a guy who literally revolutionized the area of space travel having developed and successfully tested first reusable rockets in the aerospace history, opening new horizons for cosmos explorations.

While advances in aeronautics are making news headlines daily, a much quieter scientific revolution is also happening in the area of “chemical space” explorations -- the one which might soon uncover novel medicines to cure diseases.

The “Why”, “How” and “When” of AI in Pharmaceutical Innovation

   by Andrii Buvailo    1377

(Edited version of this post originally appeared in Forbes)

“It is not the strongest of the species that survives, nor the most intelligent, but the one most adaptable to change” -- Leon C. Megginson

Last year brought about new hope and even more hype around the idea of applying artificial intelligence (AI) for “revolutionizing” drug discovery research -- via machines being able to “learn” chemistry and biology from vast amounts of experimental data to propose potent drug candidates, accurately predict their properties and possible toxicity risks. It is supposed to dramatically minimize failures in clinical trials -- saving R&D budgets, time, and most importantly, lives of patients.

How AI Is Applied To Metabolomics To Identify New Targets And Drugs

   by Andrii Buvailo    1516

The team at MIT created the most comprehensive database of metabolites, their interactions with proteins, protein-protein interactions, drug-protein interactions, and associations of metabolites with diseases. They then use the obtained interactions map to make inferences about the disease mechanisms and novel targets. With this new technology, the team launched a biotech startup ReviveMed in 2016 having raised $1.5M of funding so far.

Artificial Intelligence For Drug Discovery Use Cases At Mind the Byte

   by David Vidal    1535
Artificial Intelligence For Drug Discovery Use Cases At Mind the Byte

Artificial intelligence (AI) has become a hot topic in the biopharmaceutical environment and nearly every pharma company in the world has embraced it hoping that it will play a major role in speeding up drug discovery, by reducing R&D costs and avoiding failure in late development stages. According to prospects, AI-driven drug discovery will lead to the development of new and more effective drugs, paving thus the way to personalized medicine.